Healthcare Mar 14, 2022 09:44 AM (GMT+8) · EqualOcean
Yiouda health learned on March 14 that Suzhou Yilian biology recently completed a round B financing of US $70 million. This round of financing is jointly led by lyfe capital and Qiming venture capital, followed by Junlian capital, zhengxingu capital and Honghui Fund (HLC). The funds raised in this round of financing will be mainly used for the clinical trial development of the company's new generation of antibody drug conjugates (hereinafter referred to as ADC) product pipeline and the early research and development of new coupling drugs. Yilian biology was founded in 2020 by talents at home and abroad with full development of innovative ADC drugs and rich company management experience. At present, it has completed the international patent layout of toxin linker technology platform, and the first project will carry out clinical trials in China and the United States this year. At the same time, it has reached project cooperation with many companies to jointly develop a new generation of antibody coupled drugs.

This text is a result of machine translation.